Cerebrolysin and Recovery After Stroke (CARS)

Maybe we are finally getting somewhere with the neuronal cascade of death. But they don't mention which of the 5 causes this addresses. So I really think they have no fucking idea what they were doing. Just a lucky shot in the dark.
http://stroke.ahajournals.org/content/47/1/151.full?sid=efa02c6c-6212-4e1d-a94b-677130172953

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

1. Dafin F. Muresanu, MD, PhD;
2. Wolf-Dieter Heiss, MD;
3. Volker Hoemberg, MD;
4. Ovidiu Bajenaru, MD, PhD;
5. Cristian Dinu Popescu, MD, PhD;
6. Johannes C. Vester;
7. Volker W. Rahlfs, PhD;
8. Edith Doppler, PhD;
9. Dieter Meier, MD;
10. Herbert Moessler, PhD;
11. Alla Guekht, MD, PhD, DMedSci

+ Author Affiliations

1. From the Department of Clinical Neurosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania (D.F.M.); Max Planck Institute for Metabolism Research, Cologne, Germany (W.-D.H.); Department of Neurology, SHR Gesundheitszentrum Bad Wimpfen GmbH, Bad Wimpfen, Germany (V.H.); Department of Neurology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania (O.B.); Department of Neurology, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania (C.D.P.); Department of Biometry and Clinical Research, IDV Data Analysis and Study Planning, Krailling, Germany (J.C.V., V.W.R.); Department of Clinical Research, EVER Neuro Pharma GmbH, Unterach, Austria (E.D., D.M., H.M.); Department of Neurology, Neurosurgery and Genetics, Russian National Research Medical University, Moscow City Hospital No. 8 for Neuropsychiatry, Moscow, Russia (A.G.); and “RoNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (D.F.M.).

1. Correspondence to Dafin F. Muresanu, PhD, Department of Clinical Neurosciences, ‘‘Iuliu Hatieganu’’ University of Medicine and Pharmacy, Victor Babes St No. 8, 400012 Cluj-Napoca, Romania. E-mail dafinm@ssnn.ro

 

Next Section

Abstract

Background and Purpose—The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo.

Methods—This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset. The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset. The primary end point was the Action Research Arm Test score on day 90.

Results—The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann–Whitney estimator, 0.71; 95% confidence interval, 0.63–0.79; P<0.0001). The multivariate effect size on global status, as assessed using 12 different outcome scales, indicated a small-to-medium superiority of Cerebrolysin (Mann–Whitney estimator, 0.62; 95% confidence interval, 0.58–0.65; P<0.0001). The rate of premature discontinuation was <5% (3.8%). Cerebrolysin was safe and well tolerated.

Conclusions—Cerebrolysin had a beneficial effect on function and global outcome in early rehabilitation patients after stroke. Its safety was comparable with that of the placebo, suggesting a favorable benefit/risk ratio. Because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.

Clinical Trial Registration—URL: http://www.clinicaltrialsregister.eu. Unique identifier: 2007-000870-21.